Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial-Reference-Cited by-同舟云学术

Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial

Published:2022-01-06 Issue:9 Volume:126 Page:1264-1270
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Ychou Marc^ORCID,Rivoire Michel,Thezenas Simon,Guimbaud Rosine,Ghiringhelli Francois^ORCID,Mercier-Blas Anne,Mineur Laurent,Francois Eric,Khemissa Faiza,Chauvenet Marion,Kianmanesh Reza,Fonck Marianne,Houyau Philippe,Aparicio Thomas^ORCID,Galais Marie-Pierre,Audemar Franck,Assenat Eric,Lopez-Crapez Evelyne,Jouffroy Claire,Adenis Antoine^ORCID,Adam René,Bouché Olivier

Funder

Unrestricted grant from Merck Serono France

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-021-01644-y.pdf

Reference26 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

2. Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011;22:2042–8.

3. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–75.